Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research report released on Thursday,Benzinga reports.

FOLD has been the topic of a number of other reports. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Guggenheim upped their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Down 5.1 %

Shares of Amicus Therapeutics stock opened at $9.07 on Thursday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of -26.68, a PEG ratio of 1.65 and a beta of 0.61. The firm’s 50-day moving average is $9.56 and its two-hundred day moving average is $10.41. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.02.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amicus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $59,000. Neo Ivy Capital Management grew its stake in Amicus Therapeutics by 501.6% during the 4th quarter. Neo Ivy Capital Management now owns 395,745 shares of the biopharmaceutical company’s stock valued at $3,727,000 after purchasing an additional 329,959 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Amicus Therapeutics by 96.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 958,671 shares of the biopharmaceutical company’s stock valued at $9,031,000 after purchasing an additional 471,902 shares during the period. Vestal Point Capital LP purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth about $31,557,000. Finally, Sovereign s Capital Management LLC acquired a new stake in shares of Amicus Therapeutics during the fourth quarter worth about $2,806,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.